Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis

Pauli, G.; Larsen, Tina H.; Rak, S.; Horak, Friedrich; Pastorello, Elide A.; Valenta, Rudolf; Purohit, Ashok; Arvidsson, Monica; Kavina, Alexander; Schroeder, Jan Walter; Mothes, Nadine; Spitzauer, Susanne; Montagut, A.; Galvain, S.; Mélac, M.; André, C.; Poulsen, Lars K.; Malling, Hans‐Jørgen

doi:10.1016/j.jaci.2008.09.017

Cited by 280 publications

(211 citation statements)

References 31 publications

Supporting

Mentioning

198

Contrasting

Unclassified

Order By: Relevance

“…Often treatment-induced increases of allergen-specific IgE are moderate and might be overcome by the induction of high levels of allergen-specific IgG [21,[48][49][50][51][52][53]. Treatmentinduced increases of allergen-specific IgE up to the fourfold baseline levels have been observed in a recent SLIT study whereas allergen-specific IgG remained very low [44,54].…”

Section: Factors Limiting the Broad Application Of Allergen-specific mentioning

confidence: 99%

“…Several studies have supported this concept. Recently, a clinical study has compared the recombinant major allergen of birch, rBet v 1, with a birch pollen extract containing the same amount of purified natural Bet v 1 [53]. The rBet v 1-based vaccine showed even additional advantages over the birch pollen extract because vaccination with rBet v 1 induced higher levels of Bet v 1-specific IgG, a greater reduction of skin sensitivity and no de novo sensitizations to other allergens were found when compared with the group of patients having received birch pollen extract.…”

Section: Past and Present Attempts For The Improvement Of Allergen-spmentioning

confidence: 99%

See 1 more Smart Citation

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Focke

Swoboda

Marth

et al. 2010

Clin Experimental Allergy

View full text Add to dashboard Cite

SummaryAllergen-specific immunotherapy (SIT) is the only specific and disease-modifying approach for the treatment of allergy but several disadvantages have limited its broad applicability. We argue that the majority of the possible disadvantages of SIT such as unwanted effects, poor efficacy and specificity as well as inconvenient application are related to the poor quality of natural allergen extracts, which are the active ingredients of all currently available allergy vaccines. Because of the progress made in the field of molecular allergen characterization, new allergy vaccines based on recombinant allergens, recombinant hypoallergenic allergen derivatives and allergen-derived T cell peptides have entered clinical testing and hold promise to reduce the side-effects and to increase the specificity as well as the efficacy of SIT. Here, we present a refined immunotherapy concept, which is based on the use of peptides derived from allergen surfaces that exhibit reduced, allergen-specific IgE as well as T cell reactivity. These peptides when fused to non-allergenic carriers give rise to allergen-specific protective IgG responses with T cell help from a non-allergenic carrier molecule. We summarize the experimental data demonstrating that such peptide vaccines can bypass allergen-specific IgE as well as T cell activation and may be administered at high doses without IgE-and T cell-mediated side-effects. Should these peptide vaccines prove efficacious and safe in clinical trials, it may become possible to develop convenient, safe and broadly applicable forms of SIT as true alternatives to symptomatic, drug-based allergy treatment.

show abstract

Section: Factors Limiting the Broad Application Of Allergen-specific mentioning

confidence: 99%

Section: Past and Present Attempts For The Improvement Of Allergen-spmentioning

confidence: 99%

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Focke

Swoboda

Marth

et al. 2010

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…Thus, the content of individual allergens in a vaccine can precisely be formulated and the potential loss of allergens destroyed during the production process of allergen extracts can be excluded. Regarding the treatment of birch pollinosis, recombinant Bet v 1 has been demonstrated to be as effective as birch pollen extract (Pauli et al, 2008). As discussed above, we propose that vaccines for the treatment of birch pollen-related food allergy should contain the disease-eliciting dietary allergens.…”

Section: Future Concepts For Treatment Of Birch Pollen-related Food Amentioning

confidence: 87%

Birch Pollen-Related Food Allergy: An Excellent Disease Model to Understand the Relevance of Immunological Cross-Reactivity for Allergy

Subbarayal¹,

Geroldinger‐Simic²,

Bohle³

2012

Allergic Diseases - Highlights in the Clinic, Mechanisms and Treatment

View full text Add to dashboard Cite

“…Detaylara dikkat edilerek hazırlanan bu "izoallerjenler"; hem blokan IgG4 tipi antikor hem de T hücre yanıtını uyarabilen epitoplara sahiptir. Rekombinasyon teknolojiyle üretilen çayır otu poleni allerjenlerinin karışımı ya da yalnızca huş (birch) polen allerjeni (Bet v 1) ile uygulanan tedavinin başarılı sonuçları rekombinan allerjenlerin beklentileri karşılayacağını düşündürtmektedir (55).…”

Section: Rekombinan Allerjen Ekstraktlarıunclassified

New Developments in the Diagnosis and Therapy of Allergic Rhinitis

Özdemir¹,

Elmas²

2017

Asthma Allergy Immunol

View full text Add to dashboard Cite

ÖZAllerjik rinit (AR) tüm yaş gruplarında görülen en sık ve kronik hastalıklardan biridir. Allerjik rinit IgE-aracılı nazal havayolunun allerjik enflamasyounu olup hapşırık, gözde kaşıntı-sulanma, burun mukozasının şişlik ve enflamasyonu ile kendini gösterir. Küresel sağlık problemi ve çocukluktan erişkinliğe kadar birçok kişiyi etkileyen ağır bir hastalıktır. Dünyada çocukluk çağı AR prevalansı %0.8 -45 arasında değişmektedir. Türkiye' de değişik bölgelerde sıklığı %2.9-44 olarak bildirilmektedir. Derlememizin amacı AR teşhis ve tedavisinde güncel tedavi ve teşhis yöntemlerini anlatmaktır. Hastalığın astım üzerine ve hastanın hayatına etkisinden dolayı AR en güvenilir ve etkin tedavi yöntemleriyle tedavi edilmelidir. İkinci kuşak antihistaminikler ve intranazal steroidler tedavinin temel taşlardır. Fakat mevcut ilaçların yeni formülasyonları (rupatadin oral solusyonu, hızlı çözünen ebastin tablet ve intranazal flutikazon propionat ve azelastin hidroklorit kombinasyonu vb.), yeni keşfedilmiş moleküller (siklesonid, bilastin, roflumilast vb.), immünolojik hedefi olan tedaviler (omalizumab gibi) ve klasik olmayan tedaviler (homeopatik yöntemler gibi) AR tedavisinde yeni ufukları temsil etmektedir. Allerjik rinitin doğru teşhis edilmesi tedavi başarısında esastır. Teşhiste ümit verici gelişmeler özgün risk molekülünü tanıyan rekombinant allerjenleri kullanan teşhis yöntemlerinden beklenmektedir. Hastaların duyarlı olduğu kişisel molekülleri tanımlayan pür doğal ve rekombinan allerjenler moleküler ya da belirlenmiş komponentin teşhis yöntemiyle saptanabilir. Böylece, belirlenmiş komponente dayalı teşhis yöntemi provokasyon testine olan ihtiyacı azaltabilir ve allerjen immünoterapisinin özgünlüğünü artırabilir. Yine teşhiste, nazal nitrik oksit (nNO) düzeyini ölçmekte günümüzde değişik yöntemler vardır. Azalmış nNO, kistik fibroz için tipik olmakla beraber, primer silyer diskinezide olduğu kadar düşük değildir. nNO'nun AR gibi üst solunum yolu hastalıklarında klinikte kullanımı yaygınlaşmamıştır. ABSTRACTAllergic rhinitis (AR) is one of the most common chronic diseases in all age groups. It is an IgE-mediated allergic inflammation of the nasal airways and is characterized by sneezing, swelling and inflammation of the nasal mucosa as well as itchy and watery eyes. It is a global health problem and a burdensome disorder affecting many people from childhood to adulthood. The prevalence of childhood AR shows wide variation throughout the world, ranging from 0.8 to 45%. The prevalence rates for different regions of Turkey ranges from 2.9 to 44%. The aim of the present review is to provide an update on AR treatment and diagnosis. Because of its burden on patient's lives and its impact on asthma, AR should be taken care of properly with effective and safe treatments. Second-generation antihistamines and intranasal steroids represent the milestone of AR therapy. New formulations of available drugs (rupatadine oral solution, ebastine fast-dissolving tablets, combination of intranasal fluticasone propionate and azelastine hydr...

show abstract

Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis

Cited by 280 publications

References 31 publications

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Birch Pollen-Related Food Allergy: An Excellent Disease Model to Understand the Relevance of Immunological Cross-Reactivity for Allergy

New Developments in the Diagnosis and Therapy of Allergic Rhinitis

Contact Info

Product

Resources

About